Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients12 by Jafari-Khouzani, Kourosh et al.
Repeatability of Cerebral Perfusion
Using Dynamic Susceptibility Contrast
MRI in Glioblastoma Patients12
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Jafari-Khouzani, K., K. E. Emblem, J. Kalpathy-Cramer, A.
Bjørnerud, M. G. Vangel, E. R. Gerstner, K. M. Schmainda,
et al. 2015. “Repeatability of Cerebral Perfusion Using
Dynamic Susceptibility Contrast MRI in Glioblastoma
Patients12.” Translational Oncology 8 (3): 137-146. doi:10.1016/
j.tranon.2015.03.002. http://dx.doi.org/10.1016/j.tranon.2015.03.002.
Published Version doi:10.1016/j.tranon.2015.03.002
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:17820698
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Repeatability of Cerebral
Perfusion Using Dynamic
Susceptibility Contrast MRI in
Glioblastoma Patients1,2
Kourosh Jafari-Khouzani*, Kyrre E. Emblem*,†,
Jayashree Kalpathy-Cramer*, Atle Bjørnerud† , §,
Mark G. Vangel*, Elizabeth R. Gerstner‡,
Kathleen M. Schmainda¶, Kamran Paynabar#,
Ona Wu*, Patrick Y. Wen**, Tracy Batchelor‡,
Bruce Rosen* and Steven M. Stufflebeam*
*Athinoula A. Martinos Center for Biomedical Imaging,
Department of Radiology, Massachusetts General Hospital,
Harvard-MIT Health Sciences & Technology, Massachusetts
Institute of Technology, Cambridge, MA, USA; †The
Intervention Centre, Rikshospitalet, Oslo University Hospital,
Oslo, Norway; ‡Massachusetts General Hospital Cancer
Center, Harvard Medical School, Boston, MA, USA;
§Department of Physics, University of Oslo, Oslo, Norway;
¶Department of Radiology & Biophysics, Medical College of
Wisconsin, Milwaukee, WI, USA; #H. Milton Stewart School
of Industrial and Systems Engineering, Georgia Institute of
Technology, Atlanta, GA, USA; **Center for Neuro-Oncology,
Dana-Farber Cancer Institute, Boston, MA, USA
OBJECTIVES: This study evaluates the repeatability of brain perfusion using dynamic susceptibility contrast magnetic
resonance imaging (DSC-MRI) with a variety of post-processing methods. METHODS: Thirty-two patients with newly
diagnosed glioblastomawere recruited. On a 3-TMRI using a dual-echo, gradient-echo spin-echo DSC-MRI protocol, the
patientswere scanned twice 1 to 5 days apart. Perfusionmaps including cerebral blood volume (CBV) and cerebral blood
flow (CBF) were generated using two contrast agent leakage correction methods, along with testing normalization to
reference tissue, and application of arterial input function (AIF). Repeatability of CBV and CBF within tumor regions and
healthy tissues, identified by structural images, was assessed with intra-class correlation coefficients (ICCs) and
repeatability coefficients (RCs). Coefficients of variation (CVs) were reported for selected methods. RESULTS: CBV and
CBFwere highly repeatablewithin tumorwith ICC values up to 0.97. However, both CBV and CBF showed lower ICCs for
healthy cortical tissues (up to0.83), healthygraymatter (up to0.95), andhealthywhitematter (WM;up to0.93). The values
of CV ranged from 6% to 10% in tumor and 3% to 11% in healthy tissues. The values of RC relative to themean value of
measurement within healthy WM ranged from 22% to 42% in tumor and 7% to 43% in healthy tissues. These
percentages show how much variation in perfusion parameter, relative to that in healthy WM, we expect to observe to
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consider it statistically significant.Wealso found that normalization improved repeatability, but AIF deconvolutiondid not.
CONCLUSIONS: DSC-MRI is highly repeatable in high-grade glioma patients.
Translational Oncology (2015) 8, 137–146
Introduction
Magnetic resonance imaging (MRI) has been used to quantify blood
perfusion of the brain for nearly a quarter of a century [1,2]. Cerebral
blood volume (CBV) and cerebral blood flow (CBF) have been
recognized as biomarkers in a number of neurological diseases, in
particular brain tumors [3]. In antiangiogenic therapy of brain tumors,
and gliomas in particular, CBV and CBF correlate with tumor grade
and response to therapy [4–7]. Changes in blood perfusion are
correlated with disease-free survival, best shown with a longitudinal
analysis of dynamic susceptibility contrast MRI (DSC-MRI) [8,9].
Monitoring the therapeutic response of anti-vasogenic drugs has
increased the interest of DSC-MRI for brain tumors [5–9]. Some
studies have shown that DSC-MRI is an imaging biomarker for cerebral
perfusion, making it useful for evaluating novel anti-vasogenic agents
[7,9]. More recently, dual gradient-echo (GE), spin-echo (SE)
DSC-MRI pulse sequences quantify vessel caliber and distinguish
low-oxygenation veins from higher oxygenation arteries within the
tumor core, which may be predictive of overall survival [10].
One aspect in the evaluation of a biomarker is the reliability and
accuracy of the measurements [11]. True changes in the measured
perfusion parameters caused by a therapy (regardless of therapy
having significant clinical outcome) may be determined by both the
measurement error and physiological variations in the tissues.
Recently, the Quantitative Imaging Biomarkers Alliance initiative
has sought to identify the sources of variation contributing to the
measurement error and to improve repeatability and reproducibility
of such quantitative imaging biomarkers. This is important to
translate imaging biomarkers into clinical trials and general practice.
In particular, intra-scanner variations contribute to the measurement
error and may be evaluated by repeatability analyses.
The repeatability of DSC-MRI is affected by both image acquisition
and post-processing. Image acquisition includes signal-to-noise ratio,
susceptibility artifact, temporal and spatial resolution, length of imaging,
motion artifact, signal saturation [12], misregistration due to frequency
shifts induced by contrast agent (CA) [13], and the degree of T1
contamination [14]. Post-processing includes the applicability of the
applied kineticmodel, accuracy in arterial input function (AIF) detection
and deconvolution, accuracy of geometric mapping of selected anatomic
regions of interest (ROIs) to the perfusion maps, and the chosen
calibration and normalization techniques.
Earlier studies have evaluated the optimalDSC image acquisition and
post-processing approaches [14–16,2]. Several studies have also
evaluated the repeatability of DSC quantification using repeated scans
[17–22]. However, most repeatability studies of brain DSC-MRI have
been performed for healthy subjects. Only one repeatability study
evaluated DSC in gliomas but had a small cohort of patients [17].
Here, we evaluate the repeatability of dual GE and SE DSC-based
perfusion on a 3-T MRI scanner using a double baseline MRI
acquisition setup in 32 patients with newly diagnosed glioblastoma.We
compare CBV and CBF from twoMRI exams taken within 1 to 5 days
in both healthy tissue and tumor using two of the state-of-the-art
leakage correctionmethods and an automated AIF detection algorithm.
By assessing the repeatability of DSC-MRI, we quantify the variations
in these measurements caused by the intra-scanner and normal biologic
variations using current methodologies, with the goal of defining true
changes of perfusion in human brain tumors. This will strengthen its
use as an imaging biomarker. We hope this study will contribute to the
understanding the sources of measurement variability in DSC-MRI.
Materials and Methods
Patients
The Institutional Review Board approved this study. Informed
consent was obtained from all patients. We recruited 40 adult patients
with newly diagnosed grade IV glioblastomas in a study of cediranib, a
small molecule pan–vascular endothelial growth factor tyrosine kinase
inhibitor, sponsored by the National Cancer Institute (R01CA129371)
[23–25]. Of 40 patients, eight were eliminated because of missing a scan
(n = 4) or inadequate image quality (n = 4). The remaining 32 patients
(19M, 13 F, age 23-75,mean 56) were included in the study. All patients
were on a stable or decreasing dose of steroids for 5 days before each scan.
The patients did not receive cediranib before or between the two scans.
No tumor had significant progression between the two scans as measured
by change in contrast enhancing tumor (ET) volume or fluid-attenuated
inversion recovery (FLAIR) hyperintensity (FH). Most tumors were
unifocal and some were midline, but these factors should not influence
the results of our analysis as we compared theDSC results within patients.
Magnetic Resonance Imaging
Each subject was scanned at two time points (hereafter referred to as
baselines 1 and 2) using an identical imaging protocol on a 3.0-T MRI
System (TimTrio; Siemens Medical Solutions, Malvern, PA). The scans
were done 1 to 5 days apart (mean ± SD = 3.7 ± 1.4) to allow the contrast
to wash out between scans. AutoAlign was used to ensure that the brain
was oriented the same way for every scan. DSC-MRI was acquired as
follows: a 78-mm slab of tissue was imaged using a dual-echo, combined
GE and SE echo planar imaging sequence, with echo times of 31 and
94milliseconds, respectively, a repetition time of 1.48 seconds, a flip angle
of 90°, and 1.2-mm in-plane (160 × 160 matrix) and 6.5-mm
through-plane resolution. A total of 100 volumes were acquired and
0.1 mmol/kg Gd-DTPA (Magnivist) was injected at 5 ml/s after
approximately 81 seconds of imaging. TheDSC acquisitionwas preceded
by a dynamic contrast-enhanced acquisition (0.1 mmol/kg Gd-DTPA
injected at 5 ml/s), and this CA injection acted as a pre-dose to minimize
errors in CBV estimates due to T1-shortening effects induced by CA
extravasation in regions of blood-brain barrier breakdown or resection.
In addition, structural images including axial FLAIRwith 0.43mm×
0.43 mm × 6 mm resolution, post-contrast T1-weighted image with
0.43 mm × 0.43 mm × 6 mm resolution, and magnetization-prepared
rapid GE (MPRAGE) with 1-mm isotropic voxels were acquired.
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Perfusion Analysis
Before perfusion analysis, potential motion artifacts (motion
between time points) in the DSC data were detected and corrected
using FSL (http://www.fmrib.ox.ac.uk/fsl/). Figure 1 shows the
analysis methods that were used in the experiments. All perfusion
analyses as described in the Supplementary Materials were
performed in a modified version of nordicICE (NordicNeuroLab
AS, Bergen, Norway).
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Figure 1. Flowchart summarizing the analysis steps for the different methods used for generation of hemodynamic images and consequent
ROI analysis. The bottom row from left to right shows FH ROI, ET ROI, healthy cortical tissues, and healthyWM and GM ROIs, respectively.
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Kinetic modeling. Two established kinetic models for CA
extravasation correction were compared: Method 1 is based on the
correction technique proposed by Weisskoff et al. [26] and later
elaborated by Donahue et al. [27] and Boxerman et al. [28]. Method
2 is based on the estimation of CA extravasation from the tissue
residue function [29]. AIF deconvolution is by default applied in
method 2, but it is an option for method 1.
AIF determination and normalization. The AIFs were deter-
mined automatically in each patient by an established clustering
method [30] that has been shown to have a good agreement with
manual AIF selection and provide physiologically plausible perfusion
estimates without user interaction [31].
Normalization to a reference tissue mask improves the reliability of
CBV and CBF measurements [32,33]. Reference tissue masks
representing unaffected gray matter (GM) and white matter (WM)
were generated automatically from the DSC images as previously
described [34,31]. A combined WM + GMmask was used to generate
the reference tissue response curves used for CA extravasation correction
according to method 1 and also to generate normalized CBV and CBF
maps by dividing the respective perfusion parameters by their
corresponding mean value in the WM + GM mask.
The CBV and CBF maps were calculated both with and without
applying AIF deconvolution (for method 1, the residue function is
corrected directly for leakage effects and CBV is then estimated from
the corrected residue function rather than from the normal raw data
integral ratio) and with and without normalization to the WM + GM
mask for both GE and SE images (Figure 1).
Image Analysis
For each subject, tumor and healthy tissue ROIs were generated as
described below for baseline 1 and mapped to baseline 2 by rigid
coregistration to ensure that the same regions were evaluated in both
baselines and to eliminate the inter-rater variations of ROI drawing. ET
was outlined on 3-dimensional (3D) post-contrast T1-weighted axial
images by an experienced neuroradiologist with 5 years of clinical
experience in brain tumor imaging [35]. Likewise, FH was outlined on
3D FLAIR images. Several cortical regions were also automatically
segmented by non-rigid registration of the Harvard-Oxford Atlas to the
MPRAGE images using ANTS [36]. Regions contralateral to the tumor
were considered “healthy” brain (see Figures 1, S1, and S2).
MPRAGE volumes were also segmented into healthy WM and GM
using FSL to create a separate label volume for the healthy (or healthier)
hemisphere (distinct from theWM+GM reference mask automatically
generated from DSC-MRI) [37]. Sample ROIs are shown in Figure 1.
Finally, all labels were mapped to the perfusion maps by rigid
coregistration in SPM (http://www.fil.ion.ucl.ac.uk/spm/). The mean
values of the generated perfusionmapswere calculatedwithin eachROI.
Statistical Analysis
Intra-class correlation coefficients (ICCs) and repeatability coeffi-
cients (RCs) were computed in MATLAB (The Mathworks, Natick,
MA) for the tumor and healthy tissue ROIs. ICC was calculated using
a two-way random effect model [38]. ICC ranges from 0 to 1 and
describes how strongly two within-subject measurements resemble
each other relative to the variation between subjects. RC represents
the estimated range of variation between the measurements so that
the difference between two measurements is expected to be between −
RC and RC for 95% of patients. RC was calculated as 1:96
ﬃﬃﬃ
2
p
σW
where
ﬃﬃﬃ
2
p
σW is equal to the standard deviation of the measurement
differences. RC reflects how much change should occur to be
considered significant [39]. For healthy tissues segmented by
atlas-based segmentation, averages of ICCs and RCs were reported.
We also calculated the ratio of RC to the mean value of the
measurement within healthy WM for selected methods. Assuming
that the mean values of perfusion parameters in healthy WM are
similar among patients, these values reported in percentage show how
much variation, due to both measurement error and physiological
variations, we may expect relative to the mean value within healthy
WM. This measure is more informative than a measure such as
within-subject coefficient of variation (CV, defined as σW/μ, where μ
is mean value), which depends on the mean value of all measurements
and thus varies with the tissue type and patient population. However,
we also reported CV for select methods.
To compare the ICC of twomethods, a bootstrapping approach with
5000 repetitions to generate samples was used for hypothesis testing
[40]. In each repetition of the bootstrap procedure, we randomly
resampled the available data with replacement such that the size of each
subsample is the same as the size of the original data. Then, the ICC
means of both methods were calculated from the generated boot-
strapped samples and compared through a mean hypothesis testing
procedure [41]. Using the false discovery rate control [42], the
significance level of each hypothesis test was corrected for multiple
comparisons with an overall significance level of 0.05.
Results
Very high repeatability was obtained for all perfusion metrics, with ICC
values N0.9 in tumor for both GE CBV and CBF after normalization.
A comprehensive table of the ICCs and RCs is provided in the
Supplementary Materials (Tables S1–S2). Overall, both methods had
excellent ICCs after normalization.Method 1 had slightly higher ICCs.
Using this method, the GE CBV maps had very high ICC within
ET (ICC = 0.96) and FH (ICC = 0.97). The same was true for
CBF (ICC = 0.97 for ET and ICC = 0.96 for FH).
Table 1 compares the ICCs, RCs, and CVs before and after
normalization using method 1 with AIF deconvolution. Normalization
always improved the ICCs of both GE and SE maps (P b .05 is
highlighted). False discovery rates are highlighted in darker gray
(corresponding to P b .0032). After normalization,WM andGMhad a
lower RC compared with tumor regions, indicating that their
intra-subject variability was lower compared with tumor regions.
Furthermore, normalization always decreased CV. For GE CBV, GE
CBF, SE CBV, and SE CBF, the CV values after normalization ranged
from 8.8% to 10.0% for ET, 6.4% to 10.4% for FH, 3.1% to 6.2% for
GM, and 2.6% to 4.8% for WM. However, since CV is dependent on
the mean value of measurements and there is variability in tumor
perfusion, we have also reported the ratios (percentages) of RCs to the
mean value of measurements within healthy WM of all subjects in
Table 1. As shown, normalization often reduced the variance resulting
in more stable measurements. Note that the high percentages of
variations for tumor regions are partly due to higher perfusion in these
regions compared to the healthy WM.
Tables 2 and 3 evaluate the effect of AIF deconvolution. Using
method 1 and when normalization was not applied, the application of
AIF deconvolution on average decreased the ICCs for GE sequence
with some P values under .05 (Table 2). This comparison was
statistically significant for SE CBF of WM. Using method 1 and when
normalization was applied, the application of AIF deconvolution on
average did not significantly change the ICCs (Table 3). In method 2,
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AIF deconvolution is applied by default. When compared with method
1 with AIF deconvolution, method 2 often trended toward lower ICCs
for GE sequence (Table 4), with some P values under .05 but not
statistically significant by false discovery rate control.
On average, ICC of both CBV and CBF within the FH region was
comparable to the ICC of the ET after normalization. For WM and
GM and healthy cortical tissues, both ICCs and RCs were generally
lower than those of the tumor regions. In particular, CBV and CBF,
respectively, had maximum ICCs of 0.95 and 0.94 in GM, 0.90 and
0.93 in WM, and 0.82 ± 0.11 and 0.83 ± 0.10 in cortical regions.
The Bland-Altman plots of the GE parametric maps of tumor, WM,
and GM regions demonstrate that both inter-subject variability and
intra-subject variability were lower in healthy WM and GM compared
with tumor regions (Figures 2 and 3). Furthermore, inter-subject
variability was lower within the FH compared with ET. Intra-subject
variability was also slightly lower (Table 1). Themean ± SD values of GE
CBV generated bymethod 1 with AIF deconvolution and normalization
were 1.65 ± 0.83 within ET, 1.36 ± 0.48 within FH, 1.63 ± 0.22 within
GM, and 1.09 ± 0.09 within WM. For SE CBV, these values were
0.99 ± 0.42, 0.95 ± 0.32, 1.31 ± 0.20, and 0.89 ± 0.09, respectively
(see Table S3 for a complete list of mean ± SD values).
High ICC values were also obtained for CBV and CBF derived
from the SE sequence within ET and FH (ICC ≥ 0.9 after
normalization) but still lower compared with the same parameters
obtained from the GE data. Using method 1 with normalization for
CBV, ICC = 0.96 within ET and ICC = 0.92 within FH (Table 1).
For CBF, ICC = 0.94 within ET and ICC = 0.88 within FH. Similar
to GE maps, the ICCs were lower within the cortical tissues in
comparison with tumor regions. Normalization often improved the
ICCs. The effect of AIF deconvolution for method 1 is shown for SE
images in Tables 2 and 3. Using method 1 and when normalization
was not applied, AIF deconvolution decreased ICC in WM (P b .05).
Table 1. Comparison of ICCs, RCs, CVs, and Ratios (Percentages) of RC and Mean Value of Measurement within Healthy WM before and after Normalization. The values Were Generated Using
Method 1 with AIF Deconvolution. Comparisons for ICCs with P b .05 Are Highlighted in Gray. Statistically Significant Comparisons Are Highlighted in Dark Gray. Higher ICCs and Lower CV and RC
Percentages Are in Boldface
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However, when normalization was applied, AIF deconvolution did
not significantly change the ICCs (Table 3). Similar to GE sequence,
when comparing with method 1 with AIF deconvolution (Table 4),
method 2 often trended toward lower ICCs (P b .05 for some SE
CBV values, yet not under the threshold of 0.0032 set by false
discovery rate control).
Discussion
Targeting blood vessels has become an attractive strategy in cancer
therapeutic interventions. The dependence of tumor growth on the
recruitment of new blood vessels by angiogenesis has inspired the
development of antiangiogenic approaches to cancer therapy. These
new agents might perform best in combination with other traditional
cytotoxic drugs, indicating that a systematic process of testing and
optimization is necessary—a process greatly aided by non-invasive
biomarkers. DSC-MRI may indeed provide such a biomarker,
notably by measuring changes in perfusion as well as microvessel
caliber that accompany response [9,10].
Translation of such biomarkers into clinical trials and practice requires
the identification of all sources of variation in the measurement, such as
variations related to image acquisition, post-processing, and physiological
variations. This is essential in determining the true changes caused by the
therapy effect. The goal is to limit the measurement error related to such
variations to reliably detect true changes. This study evaluated the
measurement error related to within-scanner and physiological
variations. This required repeated scans on the same scanner and we
referred to it as repeatability and may be evaluated by the ICC and RC
values [43,44]. We identified post-processing methods that have smaller
contribution to the measurement error and showed that the resultant
measurement error is small relative to inter-subject variation, resulting in
Table 3. Comparison of ICCs before and after AIF Deconvolution. The ICCs Were Generated Using Method 1 with Normalization. The Differences between ICCs Were Not Statistically Significant
GE SE
CBV CBF CBV CBF
ROI Before After Before After Before After Before After
Enhancing Tumor 0.96 0.96 0.96 0.97 0.96 0.96 0.95 0.94
FLAIR Hyperintensity 0.97 0.97 0.95 0.96 0.92 0.92 0.93 0.88
Gray Matter 0.95 0.95 0.93 0.94 0.87 0.87 0.87 0.87
White Matter 0.90 0.89 0.88 0.93 0.76 0.75 0.76 0.65
Cortical Tissues (Mean±SD) 0.82 ± 0.11 0.82 ± 0.11 0.83 ± 0.10 0.81 ± 0.12 0.71 ± 0.14 0.70 ± 0.14 0.74 ± 0.09 0.72 ± 0.13
Table 2. Comparison of ICCs before and after AIF Deconvolution. The ICCs Were Generated Using Method 1 without Normalization. Comparisons with P b .05 Are Highlighted in Gray.
Statistically Significant Comparisons Are Highlighted in Dark Gray
Table 4. Comparison of ICCs for Methods 1 and 2. The ICCs Were Generated with AIF Deconvolution and Normalization. Comparisons with P b .05 Are Highlighted in Gray
GE SE
CBV CBF CBV CBF
ROI 1 2 1 2 1 2 1 2
Enhancing Tumor 0.96 0.91 0.97 0.97 0.96 0.94 0.94 0.95
FLAIR Hyperintensity 0.97 0.95 0.96 0.96 0.92 0.90 0.88 0.88
Gray Matter 0.95 0.90 0.94 0.94 0.87 0.70 0.87 0.86
White Matter 0.89 0.78 0.93 0.93 0.75 0.42 0.65 0.63
Cortical Tissues (Mean±SD) 0.82±0.11 0.75±0.13 0.81±0.12 0.81±0.12 0.70±0.14 0.44±0.16 0.72±0.13 0.72±0.13
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improved repeatability. The AIF deconvolution had large contributions
to the measurement error. This may be due to the variability introduced
by AIF detection despite showing good agreement with manual AIF
detection in previous studies [30,31]. However, normalization signifi-
cantly reduced such post-processing variations. AIF deconvolution may
be beneficial for the estimation of regional flow variations (delay), CA
leakage correction [29], and inMRI-based vessel caliber imaging and also
multimodal image comparisons where a pseudo-quantitative CBV value
might be relevant [45,46,31]. In this study, the reference tissues were
generated automatically. Manual ROI selection would add some user
bias, as it is difficult to place the ROIs in exactly the same positions in
both sessions.
TheWMGECBV was slightly higher than 1 (1.09 ± 0.09), whereas
WM SE CBV was slightly lower than 1 (0.89 ± 0.09). Note that the
nordicICE WM/GM segmentation algorithm removes macroscopic
vessels since the method is based on segmentation from hemodynamic
features derived from the voxel-wise time-intensity curves. WM
segmentation from structural scans will, however, include vessels leading
to an increase in relativeWMCBV. As vessels aremuchmore prominent
in GE DSC than in SE DSC, they contribute to more elevated CBV
values in GE compared to SE.
Note that since the ICC is related to the ratio of inter-subject
variability to intra-subject variability, it measures the sensitivity of the
measurement in distinguishing differences between subjects. Tumor
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Figure 2. Bland-Altman scatter plots of the GE parametric maps within ET and FH ROIs generated by method 1 with AIF deconvolution
and normalization. The dotted lines on the left show the 95% confidence interval.
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regions had higher ICC values in comparison with healthy tissues
despite having larger RC values, mainly due to larger inter-subject
variance. To determine what level of change in the perfusion
parameter should be observed to be confident that there is a true
change in the parameter, the RC may be used [11]. The ability to
determine that perfusion remains unchanged is part of the same
assessment. We reported the values of RC relative to the mean value
within healthy WM. The CV values were under 11%. This is very
well in line with the goals of Quantitative Imaging Biomarkers
Alliance that aims at reaching CV b 20%. Table 1 reveals that a
change in GE CBV of ET greater than 42% relative to the mean value
of CBV within WM may be considered significant with a 95%
confidence (42% × 1.09/1.65 = 28% compared to the mean value
within tumor). CBV RC is 22%, 13%, 7%, and 36% for GE CBV of
FH, GM, WM, and healthy cortical tissues, respectively. For other
perfusion parameters, relative RC values are reported in Table 1.
This study evaluated the repeatability of mean relative CBV (rCBV)
and relative CBF. We chose mean value due to the variability of
perfusion within the tumors. Other measurements such as maximal
rCBV and relative CBF may also be used to evaluate tumor malignancy
[47], but mean rCBV is the most commonly reported when measuring
tumor response. We did not exclude patients who had prior surgery.
Hemorrhage and post-surgery signal dropout had little impact on our
measurements since such signal dropout is primarily an issue
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Figure 3. Bland-Altman scatter plots of the GE parametric maps within WM and GM ROIs generated by method 1 with AIF deconvolution
and normalization. The dotted lines on the left show the 95% confidence interval.
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immediately after the surgery, whereas our patients were weeks/months
away from the surgery. In addition, such changes affect both baselines
similarly and have little impact on the repeatability analysis. Similarly,
tumor hemorrhage and calcification as well as steroid have little effect
on the repeatability analysis since they have similar effects on both
baseline images.
To translate DSC-MRI into general practice, other sources of
variations such as between-scanner variations and inter-rater variations
for ROI placement need to be evaluated. This requires evaluation of a
data set with each patient scanned on different scanners and is referred to
as the reproducibility study. We had acquired both images on the same
scanner and had eliminated the inter-rater variations bymapping theROI
of visit 1 to visit 2. This allowed us to independently evaluate the
within-scanner and physiological variations. We generated the perfusion
maps using readily available software. Although thismakes the translation
ofDSC-MRI to clinical practicemore feasible, reproducibility across such
post-processing software tools will be evaluated in future studies.
In conclusion, GE and SE DSC maps are highly repeatable
demonstrated by an optimized double baseline protocol. Normali-
zation of the derived perfusion metrics to corresponding values in
healthy tissue increases the repeatability of measurements, but AIF
deconvolution may decrease it. Therefore, for most clinical scenarios,
a normalized CBV or CBF without AIF deconvolution is acceptable
and produce repeatable values.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2015.03.002.
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